OV-IL15C plus EGFR-CAR-NK cells synergistically suppressed tumor growth and significantly improved survival compared with either monotherapy, correlating with increased intracranial infiltration and activation of NK and CD8+ T cells and elevated persistence of CAR-NK cells in an immunocompetent model. Collectively, OV-IL15C and off-the-shelf EGFR-CAR-NK cells represented promising therapeutic strategies for GBM treatment to improve the clinical management of this devastating disease (174). This evidence concerns the gene EGFR and neoplasm.